Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study

Abstract

in 16.0% of patients and 8.4% were considered by investigators to be treatment-related. SAEs were reported in 8.4% of patients, and 1.7% were treatment-related. For all efficacy -evaluable patients, the overall ORR of all cohorts was 61.0% and DCR was 89.0%, per independent radiological review committee review. And in 180 mg cohort, the overall ORR was 68.1% and DCR was 95.7%. The ORR for BM was 38.8% across all doses and 45.8% in 180 mg cohort, and DCR for BM was 98.0% and 100% for overall and 180 mg groups. The median progression-free survival was 9.92 months (not mature). Conclusions: BPI-7711 achieved a high overall ORR and promising BM efficacy in NSCLC patients. The safety profile and antitumor activity support continued development of BPI-7711. Phase 2 studies are under preparation.